Literature DB >> 2442425

Comparison of calcium antagonist properties of antispasmotic agents.

S B Malkowicz, A J Wein, M R Ruggieri, R M Levin.   

Abstract

Several agents commonly employed for the treatment of detrusor hyperreflexia or instability are characterized as antispasmotics. Their mechanism of action is not completely understood but it has been proposed that their actions are dependent on anticholinergic activity, CNS mediated relaxation, or local anesthetic properties. The purpose of this study was to determine if imipramine, flavoxate HCl, or oxybutynin HCl possess any calcium antagonist properties. This was accomplished by determining the ability of these agents to inhibit a standard cholinergic stimulus (200 uM bethanechol) over a range of extracellular calcium concentrations (0.5 to 10.0 mM). In-vitro isolated smooth muscle strips of rabbit bladder dome were utilized. Control tissues displayed a reproducible response to bethanechol stimulation at different calcium concentrations with an ED50 of 0.4 mM calcium and a peak response of 5.0+/-0.4 grams tension. Flavoxate (2.5 mM), oxybutynin (2.5 uM), and imipramine 25 uM) all significantly reduced peak tension generation. The ED 50's for extracellular calcium in the presence of flavoxate and oxybutynin were not significantly different from controls. Imipramine at both 3 and 25 uM significantly increased the ED50 for calcium. The above data demonstrate that imipramine possesses competitive calcium antagonism. The relative contribution of calcium antagonism toward the inhibitory effects of imipramine is unknown but may play a significant role in its clinical activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2442425     DOI: 10.1016/s0022-5347(17)43295-2

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

1.  The effects of flavoxate hydrochloride on voltage-dependent L-type Ca2+ currents in human urinary bladder.

Authors:  Toshihisa Tomoda; Manami Aishima; Naruaki Takano; Toshiaki Nakano; Narihito Seki; Yoshikazu Yonemitsu; Katsuo Sueishi; Seiji Naito; Yushi Ito; Noriyoshi Teramoto
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

2.  Effects of papaverine on human isolated bladder muscle.

Authors:  L Hertle; H Nawrath
Journal:  Urol Res       Date:  1990

3.  Psychotic disorder induced by oxybutynin: Presentation of two cases.

Authors:  Murat Gulsun; Murat Pinar; Unal Sabanci
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 4.  Flavoxate in urogynecology: an old drug revisited.

Authors:  Murat Zor; Emin Aydur; Roger Roman Dmochowski
Journal:  Int Urogynecol J       Date:  2014-12-06       Impact factor: 2.894

5.  Effects of papaverine on tension and 45Ca-uptake in isolated urinary bladder.

Authors:  W Diederichs
Journal:  Urol Res       Date:  1991

6.  Oxybutynin extended-release: a review of its use in the management of overactive bladder.

Authors:  M Asif A Siddiqui; Caroline M Perry; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Transdermal oxybutynin: for overactive bladder.

Authors:  Lynne M Bang; Stephanie E Easthope; Caroline M Perry
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 8.  Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.

Authors:  Y E Yarker; K L Goa; A Fitton
Journal:  Drugs Aging       Date:  1995-03       Impact factor: 3.923

Review 9.  The Pharmacology of Visual Hallucinations in Synucleinopathies.

Authors:  Mirella Russo; Claudia Carrarini; Fedele Dono; Marianna Gabriella Rispoli; Martina Di Pietro; Vincenzo Di Stefano; Laura Ferri; Laura Bonanni; Stefano Luca Sensi; Marco Onofrj
Journal:  Front Pharmacol       Date:  2019-12-09       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.